Heparin-induced thrombocytopenia type II represents a serious side effect of heparin therapy. Immune-mediated platelet activation results in thrombocytopenia, endothelial thrombin release and development of thrombosis, mainly venous. We report the case of a subarachnoid hemorrhage patient developed severe heparininduced thrombocytopenia type II after heparin administration to maintain double-lumen central venous catheter. The patient was treated with a new anticoagulant regimen, argatroban. There were no complications and platelet counts were restored to normal levels.
|Number of pages||5|
|Publication status||Published - 2005|
ASJC Scopus subject areas